secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001802768-23-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q1 adjusted cash receipts $1,131M (+87% YoY); reaffirms FY guidance $2,850-2,950M
--------------------------------------------------------------------------------

- Adjusted Cash Receipts $1,131M, +87% YoY; underlying growth 11% ex-Zavzpret milestone and Biohaven payments.
- GAAP net cash from ops $1,034M (+125% YoY) includes $475M Zavzpret milestone and $35M Airsupra payment.
- Announced up to $1.6B in new royalty deals (Spinraza, pelacarsen, KarXT) and $1.0B share buyback program.
- Reaffirmed FY23 Adjusted Cash Receipts guidance $2,850-2,950M (underlying growth 4-9% ex-milestones).
- Portfolio milestones: FDA approvals for Zavzpret, Airsupra, Trodelvy; positive Xtandi Phase 3 data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000180276823000013/0001802768-23-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000180276823000013/rprx-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001802768-23-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer